Bio
Ken is a serial entrepreneur, having co-founded 8 biotech companies with a specialization in infectious diseases. Today he serves as Chairman of the Board of 5 biotech companies, each developing medical countermeasures to infectious diseases.
Ken took his first company IntraBiotics, an antibiotic company, public on the Nasdaq in 2000. His second company Fluxion Biosciences was profitable and sold recently. His third company, PaxVax, a vaccine company, developed a cholera vaccine and commercialized it along with a typhoid vaccine before being sold to Emergent Biosolutions.
Ken was a Harvard Advanced Leadership Initiative Fellow (2015), an AIMBE (American Institute for Medical and Biological Engineers) 2016 and a White House Presidential Executive Fellow (2016-2017). After government service, Ken returned to California to co-found infectious disease companies based on technologies from NIH, BARDA and DARPA.
Long ago, Ken was biotech venture capitalist with 20+ years of Ser A investing experience in 48 companies with more than 36 successful IPOs or M&A exits at Institutional Venture Partners (IVP), Latterell Venture Partners (LVP) and his own fund (K2).
